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Abstract
Numerous human tumor types, including ovarian
cancer, display a significant expression of the CD44
family of cell surface proteoglycans. To develop tumor-
targeted drugs, we have initially evaluated whether the
CD44 ligand hyaluronic acid (HA) could serve as a
backbone for paclitaxel (TXL) prodrugs. HA-TXL was
prepared by modification of previous techniques. The
in vitro cytotoxicity of HA-TXL against the CD44(+)
human ovarian carcinoma cell lines SKOV-3ip and
NMP-1 could be significantly blocked by preincubation
with a molar excess of free HA. Female nude mice
bearing intraperitoneal implants of NMP-1 cells were
treated intraperitoneally with a single sub–maximum to-
lerated dose dose of HA-TXL or with multiple-dose re-
gimens of paclitaxel (Taxol; Mead Johnson, Princeton,
NJ) to determine the effects of these regimens on host
survival and intraperitoneal tumor burden, with the
latter being assessed by magnetic resonance imaging.
NMP-1 xenografts were highly resistant to Taxol regi-
mens, as host survival was only nominally improved
compared to controls (T/C f 120), whereas single-
dose HA-TXL treatment significantly improved survi-
val in this model (T/C f 140; P = .004). In both NMP-1
and SKOV-3ip models, MR images of abdomens of
HA-TXL–treated mice obtained shortly before controls
required humane sacrifice revealed markedly reduced
tumor burdens compared to control mice. This study
is among the first to demonstrate that HA-based pro-
drugs administered locoregionally have antitumor ac-
tivity in vivo.
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Introduction
The majority of newly diagnosed ovarian cancers extend
beyond the ovary and, in particular, involve the peritoneum
[1–5]. Following surgical debulking, adjuvant chemo-
therapy treatment with platinum-containing and taxane-
containing regimens results in high initial response rates,
but most patients relapse with drug-resistant disease,
hence the poor 5-year survival rates [1–6]. In a very note-
worthy development, recent clinical trial results have provided
compelling evidence that intraperitoneal administration of
these drugs results in markedly improved survival in small-
volume disease patients compared to intravenous administra-
tion [7–10]. This is an encouragement to develop new agents
and/or drug formulations for intraperitoneal therapy.
Macromolecular drug copolymers [e.g., poly-L-glutamic acid–
paclitaxel (PGA-TXL or XYOTAX)] have been developed as
one approach to overcoming drug resistance. In preclinical and
clinical studies, XYOTAX has demonstrated reduced toxicity,
enhanced tumor accumulation, and greater antitumor efficacy
compared to paclitaxel (Taxol; Mead Johnson, Princeton, NJ)
[11–16]; of note, this paclitaxel prodrug is in advanced clinical
trials in ovarian cancer, non–small cell lung cancer, and other
carcinomas [17–22].
We reasoned that whereas PGA-TXL is likely restricted to
uptake by fluid-phase pinocytosis, a paclitaxel copolymer that
could exploit the selectivity and efficiency of receptor-mediated
uptake might demonstrate even greater improvements in
toxicity/efficacy parameters. The CD44 proteoglycan family,
comprised of a parental form and 10 or more isoforms that
are major receptors for hyaluronic acid (HA), is expressed in as
high as f 90% of fresh samples from primary human ovarian
tumors or peritoneal implants [23–29]. We proposed, as have
others, that an HA backbone in a paclitaxel (TXL) copolymer
(HA-TXL) might allow efficient and specific receptor-mediated
prodrug uptake by CD44. The use of a hydrophilic HA back-
bone would both overcome the limited aqueous solubility
of paclitaxel without resorting to the use of an excipient as
in Taxol and would allow multiple sites for paclitaxel loading
onto a single HA scaffold to be internalized by one or more
CD44 molecules.
In the current study, we prepared a lead formulation of
HA-TXL and evaluated its toxicity parameters, as well as its
antitumor activity, in two CD44(+) human ovarian carcinoma
nudemouse xenograft models. Our results, the first to establish
these in vivo characteristics of such an HA-based prodrug,
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indicate that even a single intraperitoneal administration of
a sub-MTD dose of HA-TXL resulted in antitumor efficacy:
reduced or eliminated tumor burden and prolonged survival
compared to controls. We propose that further development
of this targeted prodrug approach is warranted.
Materials and Methods
Cell Lines
A cisplatin (CDDP)–resistant cell line was first developed
from parental OVCAR-3 cells (American Type Culture Col-
lection, Manassas, VA) by in vitro incubation with increasing
concentrations of CDDP [30]. Cells surviving several rounds
of selection in CDDP-containing medium were cloned by
limiting dilution, expanded, and retested for CDDP resis-
tance. NMP-1 cells were derived from ascites of nude mice
into which these CDDP-resistant OVCAR-3 cells had been
implanted intraperitoneally [15,31].
The origin of the SKOV-3 ovarian adenocarcinoma cell
line has been described previously [32,33]. The SKOV-3ip
cell line used in the current study was derived from it by
selection from an intraperitoneally implanted SKOV-3 xeno-
graft, provided through the courtesy of Dr. I. J. Fidler.
HA-TXL Synthesis
HA (f 40 kDa) was provided by K3 Corporation (Great
Falls, VA). 1-Ethyl-3-[3V-(dimethylamino)propyl]carbodiimide
(EDCI), diphenylphosphoryl chloride, adipic dihyrazide (ADH),
succinic anhydride, N-hydroxysuccinimide (NHS), and triethyl-
amine were purchased from Sigma-Aldrich Co. (Milwaukee,
WI). Paclitaxel (Taxol) was purchased from HandeTech De-
velopment Co. (Houston, TX). All solvents were of reagent
or high-performance liquid chromatography (HPLC) grade.
Analytic instrumentation Nuclear magnetic resonance
(NMR) spectral data were obtained on a 300-MHz or a
500-MHz Bruker Advance Spectrometer (Fallanden, Swit-
zerland). UV–Vis spectra were recorded on a Perkin-Elmer
spectrometer (Perkin-Elmer, Waltham, MA). HPLC was car-
ried out on a Waters Model 2695 system (Waters Corpora-
tion, Milford, MA) equipped with a C-18 column and a 2996
photodiode detector using H2O–CH3CN (60:40) as eluent at
a flow rate of 1 ml/min.
Synthesis of Taxol–NHS ester The reported synthesis of
Luo and Prestwich [34] and Luo et al. [35] was followed. To a
stirred solution of paclitaxel (540 mg, 0.63 mmol) and suc-
cinic anhydride (76mg, 0.76 mmol) in CH2Cl2 (25 ml) at room
temperature was added dry pyridine (513 ml, 6.3 mmol). This
reaction mixture was stirred for 3 days at room temperature
and then concentrated in vacuo. The residue was dissolved
in CH2Cl2 (5 ml), and the product was purified by silica gel
column chromatography (ethyl acetate–hexane, 1:1) to yield
Taxol-2V-hemisuccinate as a white solid (85%).
N-hydroxysuccinimido diphenyl phosphate (SDPP) was
prepared from diphenylphosphoryl chloride, NHS, and tri-
ethylamine in CH2Cl2, as previously described [34,35]. The
crude product was triturated with ether, dissolved in ethyl ace-
tate, washed with H2O, and dried over MgSO4. The concen-
tration of the organic layer in vacuo gave pure SDPP (85%).
To a solution of Taxol–hemisuccinate (300 mg, 0.31 mmol)
and SDPP (164 mg, 0.46 mmol) in acetonitrile (15 ml) was
added 175 ml (1.2 mmol) of triethylamine. The reaction was
stirred for 6 hours at room temperature and then concentrated
in vacuo. The residue was dissolved in ethyl acetate/hexane
and purified by silica gel column chromatography (ethyl
acetate–hexene, 1:2). Taxol–NHS ester was dried for
24 hours in vacuo at room temperature to give 265 mg (80%).
Synthesis of adipic dihydrazidofunctionalized HA (HA-
ADH) HA-ADH was prepared according to the method of
Bulpitt and Aeschlimann [36]. Briefly, HA was dissolved in
water to give a concentration of 3 mg/ml. To this solution was
added a 30-fold molar excess of ADH. The pH of the reaction
mixture was adjusted to 6.8 with 0.1 M NaOH/0.1 M HCl. One
equivalent of EDCI was added in solid form followed by 1 Eq
of 1-hydroxybenzotriazole in dimethyl sulfoxide–H2O (1:1)
solution. The pH of the mixture was maintained at 6.8 by
the addition of 0.1 M NaOH, and the reaction was allowed to
proceed overnight. The reaction was quenched by the ad-
dition of 0.1 N NaOH (pH 7.0). The mixture was then trans-
ferred to pretreated dialysis tubing and dialyzed exhaustively
against 100 mM NaCl, 25% EtOH/H2O, and, finally, H2O. The
solution was filtered through a 0.2-mm cellulose acetate mem-
brane, flash frozen, and lyophilized. The purity of HA-ADH
was determined by HPLC. The extent of substitution of HA
with ADH was determined by the ratio of methylene hydro-
gens to acetyl methyl protons, as measured by [1H]NMR.
Synthesis of HA-TXL In initial experiments, we followed
the method reported by Luo and Prestwich [34] and Luo et al.
[35] but were only able to obtain low yields (V 10%), which
are insufficient to support in vivo studies. Instead, we syn-
thesized HA-TXL as described below, with the major change
being a higher pH for final coupling, and we were able
to consistently obtain moderate to high yields (z 50%).
HA-ADH (75 mg) was dissolved in 0.1 M NaHCO3 buffer
(pH 8.5) at a concentration of 1 mg/ml. To this solution was
added Taxol–NHS ester (18 mg) dissolved in sufficient
DMF–H2O (2:1, vol/vol) to give a homogeneous solution.
The reaction mixture was stirred at room temperature for
24 hours and then evaporated to dryness in vacuo (37jC).
The residue was dissolved in H2O, and the product was
purified by gel filtration chromatography (Biogel P-10; Bio-
Rad, Hercules, CA) using water as eluent. Fractions con-
taining HA-TXL, as evidenced by HPLC analysis, were
combined and lyophilized. The [1H]NMR spectrum of the
product showed phenyl resonances at 7.25 to 8.15 ppm,
affording proof of HA-TXL formation. The purity of the pro-
duct was determined by HPLC analysis. The percentage of
incorporated paclitaxel was determined by UV absorbance
(Taxol: kmax = 227 nm, e = 2.8  104). In this manner, con-
jugates with up to f 10% of the carboxyl groups modified
were prepared; this level of substitution would leave z 90%
of disaccharides intact and available for CD44 binding
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and would produce conjugates containing f 15% to 20%
paclitaxel (wt/wt). For in vitro and in vivo studies, paclitaxel
equivalents in terms of concentration andmass, respectively,
were calculated for each batch of prepared HA-TXL.
In Vitro Cytotoxicity Assays
NMP-1 and SKOV-3ip cells (1  104 cells/well) were
cultured overnight in 96-well plates in 100 ml of medium
(Dulbecco’s modified Eagle’s medium/F12; Life Technolo-
gies, Inc., Gaithersburg, MD) supplemented with 5% fetal
calf serum/well before treatment. The cytotoxic effects of
HA-TXL were established using a dose range of up to 4 mg/ml
(paclitaxel equivalents). Remaining viable cells were stained
with neutral red after up to 96 hours, and the percentage of
control cell survival as measured by the optical density of
incorporated dye was determined. The results from two to
four experiments of each type are shown. In competition
studies, cells were pretreated with a 100-fold molar excess of
free HA before 4 hours of incubation with HA-TXL; free HA
and HA-TXL were washed off the plate, and fresh medium
was added for the rest of the 72-hour incubation period.
In Vivo Efficacy Assays
NMP-1 This study was designed to give quantitative sur-
vival data as criteria for the antitumor efficacy of HA-TXL and
for its comparison to Taxol. On day 0, about 1  107 viable
NMP-1 cells were injected into the peritoneal cavities of
groups of 6- to 9-week-old female nude mice (Harlan
Sprague Dawley, Indianapolis, IN). Five or more mice per
experimental group were used as the basis for statistical
analyses. Administration of drugs was initiated 1 week later
(day 7). Complete necropsy and histopathological evalua-
tion, as well as MR imaging analysis, of mice in parallel
studies indicated that, within 7 days of intraperitoneal in-
oculation, abdominal tumors were already present [15,37].
Taxol was administered intraperitoneally on a schedule of
every 7 days 3, at either 10 or 15 mg/kg; doses higher than
this frequently resulted in marked toxicity and/or death in our
hands [15]. HA-TXL (14% paclitaxel by weight) was admin-
istered in a single intraperitoneal dose of up to 300 mg/kg
in pilot studies, and 180 mg/kg HA-TXL (18% paclitaxel by
weight) was used in the main study—the same dose as
previously used in preclinical ovarian carcinoma xenograft
studies with PGA-TXL [15]. NMP-1–implanted mice devel-
oped marked ascites as one of the earliest clinical signs of
peritoneal tumor and before other aspects of tumor progres-
sion became apparent; ascitic fluid was repeatedly removed
from mice at intervals, beginning around the fourth week.
Eventually, cachexia, spine prominence, and other morbid
symptoms became more severe, and these animals were
humanely sacrificed by carbon dioxide asphyxiation. For any
tumor-bearing mice that succumbed between daily observa-
tions and before the opportunity to sacrifice them, the day of
death was considered to be the day before the date they
were discovered as deceased. The day of humane sacrifice
or death was recorded for each mouse, and these values
were compared among control and treatment groups by
paired or unpaired Student’s t test for survival analyses.
SKOV-3ip This study was conducted similarly to those
described for the NMP-1 model, except that the mice were
subjected to magnetic resonance (MR) imaging–based
quantification of remaining tumor volumes at a common
end point, rather than being taken to a survival end point.
Furthermore, 1  106 to 2  106 cells were injected intra-
peritoneally, and treatment with HA-TXL was not initiated
until day 14.
MR Imaging Analyses
MR imaging studies were conducted at theM. D. Anderson
Cancer Center Small Animal Imaging Facility (SAIF). Previous
studies [37] revealed that these orthotopic intraperitoneal
human ovarian carcinoma xenograft models initially pre-
sented either as numerous widely dispersed foci of individual
and coalescing solid tumors throughout the peritoneal cavity
or as more solid masses that appeared to originate adjacent
to and around the pancreas. Respiratory-gated T2-weighted
(TE = 45.0milliseconds; TR = 1215.6 milliseconds; thickness =
0.5 mm; space between images = 0.3 mm) coronal images
were used for the initial evaluation of tumor distribution and
growth in these models; images of the abdomens of these
mice were acquired using a Bruker 4.7-T, 40-cm Biospec MR
scanner (Bruker Biospin USA, Billerica, MA). Preliminary
studies had demonstrated that peritoneal tumors as small as
500 mm in diameter were detectable; generally, MR imaging–
based evidence of tumor was first clearly detected on day 7
(NMP-1) and day 14 (SKOV-3).
In NMP-1 studies, mice were held for survival end points.
In SKOV-3ip studies, tumor measurements were performed
using the Image J program (National Institutes of Health,
Bethesda, MD). Regions of interest were drawn on each
image that contained a tumor and then multiplied by slice
thickness to obtain tumor volume. If the tumor was seen in
several contiguous slices, then tumor volumes were added
together. To avoid overestimation of tumor size, one half of
the volume from the most dorsal and ventral images con-
taining the tumor was used in volume analysis. Assuming
a tumor density of 1 g/ml, tumor volumes (mm3) were
converted to weight (g) for analysis [38].
Results and Discussion
Cytotoxic Specificity of HA-TXL In Vitro
The human ovarian carcinoma cell lines NMP-1 and
SKOV-3ip were determined to be CD44(+) by flow cytometry
(data not shown). Initial in vitro experiments were designed
to establish whether the uptake and subsequent cytotoxic
effects of HA-TXL on these cell lines were CD44-specific.
The results in Table 1 demonstrate that, for both cell lines,
preblocking of HA binding sites with free HA inhibited the
ability of HA-TXL to reduce target cell survival. This result
reflects the predominant role of receptor (CD44)–specific
uptake, compared to nonspecific pinocytosis, of HA-TXL;
however, the latter route of uptake should still be operant,
leading to some non–HA-inhibitable uptake by and cyto-
toxicity in CD44(+) cells, as well as with CD44() cells.
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These results are in good agreement with those of Luo et al.
[35] who demonstrated CD44-specific uptake and internali-
zation of fluorescently labeled HA and cytotoxicity of HA-TXL
against CD44(+) SKOV-3 and other tumor cells, whereas
HA-TXL was ineffective against CD44() NIH 3T3 target
cells. The relatively flat dose response of cytotoxicity versus
HA-TXL concentration in our studies is reminiscent of the
response to free Taxol that we have previously observed with
NMP-1 and HEY ovarian carcinoma models [15] and, in that
light, makes the observed extent of blockade with free HA
more compelling.
Preliminary Toxicity Studies of HA-TXL
Mice were injected intraperitoneally with HA-TXL at doses
of up to 300 mg/kg (paclitaxel equivalents), and these mice
were held for observation for at least 6 months. The mice
were found to tolerate even the highest dose administered,
indicating that this formulation was far less toxic than free
paclitaxel (Taxol). Furthermore, the 250- and 300-mg/kg
doses exceeded the highest dose we had previously used
(200 mg/kg) with another paclitaxel prodrug PGA-TXL [15],
suggesting that HA-TXL might have an even higher mouse
MTD than PGA-TXL. It is also considerably higher than the
100-mg/kg dose recently reported as the MTD for another
HA–paclitaxel prodrug formulation, HYTAD1-p20 [39].
Antitumor Efficacy of HA-TXL
We next evaluated both MR imaging–based antitumor
effects and effects on survival following HA-TXL treatment in
CD44(+) NMP-1 and SKOV-3ip orthotopic (intraperitoneal)
xenograft models.
NMP-1 In a pilot efficacy experiment, mice bearing NMP-1
xenografts received an intraperitoneal injection of HA-TXL
(100 or 200 mg/kg, paclitaxel equivalents) on day 8 post–
tumor implantation. Control mice survived for an average of
34 days, mice treated with 100 mg/kg HA-TXL survived to
day 60, and mice treated with 200 mg/kg HA-TXL were
sacrificed on day 199 and judged tumor-free by MR imaging
(Figure 1; compare with controls in Figure 3A).
In an expanded efficacy experiment, groups of NMP-1–
implanted mice were treated either with vehicle, with multiple-
dose regimens of Taxol (using 10 or 15 mg/kg; higher doses
on this schedule are toxic), or with a single injection of
HA-TXL. Effects on survival are shown in the Kaplan-Meier
survival plot in Figure 2 and are summarized in Table 2. In
addition, two of five mice in each group were MR-imaged on
day 28 post–tumor inoculation before any mice required
sacrifice. NMP-1–implantedmice responded toHA-TXL treat-
ment with a T/C f 140 (Figure 2; P = .004 by Mantel-Cox)
and showed markedly reduced tumor burden (Figure 3D)
compared to controls (Figure 3A). In contrast, multiple-dose
regimens of Taxol at either dose level were essentially inactive
in this model, both by MR imaging (Figure 3B for 10 mg/kg;
Figure 3C for 15 mg/kg) and survival criteria (Figure 2; T/C
f 105 for 10 mg/kg and T/Cf 120 for 15 mg/kg).
Table 1. Specificity of HA-TXL Cytotoxicity against CD44(+) Human Ovarian
Carcinoma Cell Lines: Blocking by Free HA.
HA-TXL % Survival (4-Hour HA-TXL Treatment)
SKOV-3ip NMP-1
5000 ng/ml 55.9 ± 7.0* 67.6 ± 4.6
+ Free HAy 104.8 ± 9.6z 86.5 ± 3.7
500 ng/ml 81.8 ± 14.5 73.0 ± 5.2
+ Free HA 101.9 ± 11.3 96.5 ± 4.1z
50 ng/ml 74.8 ± 12.3 78.7 ± 4.0
+ Free HA 91.6 ± 8.5z 79.3 ± 4.5
*Mean ± SEM compared to untreated or HA-treated controls.
yOne-hundred– fold molar excess HA equivalents, preincubated for 4 hours
prior to HA-TXL addition.
zP < .03 (t-test) versus HA-TXL without preblocking.
Figure 1. T2-weighted coronal MR image of the abdomen of an NMP-1–
implanted nude mouse (199 days following tumor inoculation) that was treated
with a single intraperitoneal injection of 200 mg/kg HA-TXL 8 days post– tumor
inoculation. No tumors were observed; compare to day 28 images of NMP-1
control mice in Figure 3A.
Figure 2. Kaplan-Meier survival plot of NMP-1– implanted mice treated
intraperitoneally either with saline (controls), with 10 or 15 mg/kg Taxol on
regimens of every 7 days  3 beginning on day 7 post – tumor implantation, or
with a single injection of 180 mg/kg HA-TXL (paclitaxel equivalents) on day 7.
T/C values were 105 and 120 for the 10- and 15-mg/kg multiple-dose Taxol
groups, respectively, and 140 for the single-dose HA-TXL group (P = .004 vs
controls; Mantel-Cox).
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SKOV-3ip Antitumor efficacy results with HA-TXL were
generally similar to those with the SKOV-3ip ovarian carci-
noma model. Necropsy examination conducted by a board-
certified veterinary pathologist (R.E.P.) on mice from the
HA-TXL treatment group found only small tumors 12 weeks
post–tumor implantation and 10 weeks posttreatment. How-
ever, control SKOV-3ip mice all presented evidence for
marked tumor involvement, typically including abdominal
distention with bloody ascites and marked abdominal tumor
burden associated with the umbilicus, diaphragm, abdominal
wall, lymph nodes, and mesentery. MR images obtained on
the day of sacrifice were analyzed by a diagnostic imaging
clinician (V.K.), and representative images are shown in
Figure 4; again, these images show clear distinctions be-
tween treated and control groups. Only small tumors were
detected in HA-TXL–treated mice (Figure 4B), whereas
significant tumor burden and resultant abdominal distention
were very apparent in control mice (Figure 4A). Quantifica-
tion of contiguous MR images demonstrated that tumor
burden in the HA-TXL–treated group was markedly reduced
compared to controls (P < .03, t-test; Figure 4C).
Thus, in the SKOV-3ip model, both MR imaging and histo-
pathological analyses support the antitumor efficacy of even a
single dose of HA-TXL administered at a sub-MTD level.
Preliminary Toxicology Studies of HA-TXL
Aside from CD44, which was originally associated with
lymphocyte activation, other HA receptors include RHAMM
(receptor for HA-mediated cell motility) and HARLEC (HA
Table 2. Response of NMP-1 Xenograft Model to Multiple-Dose Taxol and
Single-Dose HA-TXL.
Treatment Mean Day of
Survival/Sacrifice
T/C
Control 31.2 ± 3.2* –
Taxol
10 mg/kg (every 7 days  3)y 32.6 ± 5.6 105
15 mg/kg (every 7 days  3)z 37.6 ± 9.3 120
HA-TXL, 180 mg/kg§ 43.6 ± 6.7 140b
*Mean ± SEM.
yTaxol regimens initiated on Day 7 post – tumor inoculation.
zHigher doses caused toxicity on this schedule.
§Single dose administered on Day 7.
bP = .004 vs controls (Mantel-Cox).
Figure 3. Representative day 28 T2-weighted coronal abdominal MR images
of NMP-1– implanted (A) control mice sham-treated with saline; arrows
indicate examples of tumor masses throughout the abdomen; note the heavy
tumor burden and areas of high signal intensity indicating ascites. (B) Mice
treated with a multiple-dose intraperitoneal injection regimen of 10 mg/kg
Taxol; arrows indicate examples of tumor masses throughout the abdomen;
note evidence for ascites. (C) Mice treated with a multiple-dose intraperitoneal
injection regimen of 15 mg/kg Taxol; note heavy tumor burden and ascites.
(D) Mice treated with a single intraperitoneal injection of HA-TXL; note the
comparatively modest tumor burden and few areas of high signal intensity
indicating ascites. B = bladder.
Figure 4. Representative day 84 coronal T2-weighted MR images of the
abdomens of SKOV-3ip– implanted mice from the control group (A) and the
180-mg/kg HA-TXL treatment group (B). Arrows indicate examples of intra-
peritoneal tumors; note the greater tumor burden in control versus treated
mice. B = bladder. Comparison of tumor weights derived from MR images of
mice bearing SKOV-3ip tumors (C; P < .03, n = 3; t-test).
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receptor, liver endothelial cells). Thus, we wanted to deter-
mine whether, as a result of the expression of HARLEC or
other HA receptors, HA-TXL treatment would be associated
with significant hepatotoxicity. In preliminary studies, we
observed only a slight elevation of serum liver transaminase
(aspartate aminotransferase = 220 U/ml; alanine amino-
transferase = 175 U/ml) and alkaline phosphatase (92 U/ml)
levels 24 hours after intraperitoneal injection of 180 mg/kg
HA-TXL. It is possible that these toxicities were secondary to
liver uptake, particularly the transaminase elevations; how-
ever, HARLEC and RHAMM are less specific for HA than is
CD44, and the former can be blocked with chondroitin sulfate
[40]. This preblocking strategy should shunt HA-TXL away
from certain normal tissues and increase uptake in tumor.
Our studies focused on CD44(+) human ovarian carci-
noma models, and the selectivity of HA-TXL for these
CD44-expressing cell lines was demonstrated in vitro by
competition experiments with free HA (Table 1); similar obser-
vations of CD44-specific uptake and cytotoxicity of HA-TXL,
as well as lack of effects against CD44() NIH 3T3 cells, have
been reported previously [34,35]. To further understand the
nature of the HA/CD44 interaction and the role it might play in
the selectivity of response to HA-TXL in vivo, a control study
would be of interest using CD44() tumor models. However,
we have not been able to define a CD44() human ovarian
carcinoma model, nor another CD44() tumor model with
peritoneal metastases, for such evaluation. Furthermore, both
potentially tumor-promoting and/or tumor-inhibiting effects
of free HA in CD44(+) models must be properly controlled
for in such analyses. Nevertheless, by employing a similar
competition strategy with coadministered free HA, it might
be possible to glean the relative roles of receptor-specific
versus pinocytotic uptake of HA-TXL in vivo with CD44(+)
tumor models.
Other studies have begun to evaluate the antitumor effi-
cacy of prodrug formulations based on an HA backbone or
ligand [37,39,41–43]. For example, butyric acid esters of HA
were prepared, and these conjugates were injected intra-
tumorally in a subcutaneously implanted syngeneic Lewis
lung carcinoma model. The growth rate of an ectopic tumor
was reduced compared to vehicle control, and both the
number and the weight of lung metastases were significantly
reduced compared to controls [41,42]. Our study differs in
several respects, including the use of an orthotopic (intra-
peritoneal) human tumor xenograft and administration of the
HA prodrug locoregionally (intraperitoneal) rather than intra-
tumorally. A recent study is more similar to ours, as it used
an HA backbone for a paclitaxel prodrug (HYTAD1-p20) [39].
In an ectopic human bladder carcinoma xenograft model in
SCID mice, multiple-dose regimens of HYTAD1-p20 admin-
istered intraperitoneally, or Taxol administered intravenously,
achieved comparable tumor growth inhibition. Nevertheless,
our results in the orthotopic NMP-1 model demonstrate su-
perior antitumor efficacy with even a single dose of HA-TXL
compared to a multiple-dose Taxol regimen.
Although we view HA as simply a backbone by which
paclitaxel (and other) chemotherapeutics might be delivered
to CD44(+) tumor cells, we did not attempt to rule out the
possibility that part of the anti-tumor effect of HA-TXL might
be mediated by the backbone itself. For example, HA may
disrupt CD44(+) tumor cell–extracellular matrix interactions,
presumably leading to anoikis, as has been observed in a
human breast carcinoma xenograft model [44]. In that light,
future comparisons of HA-TXL antitumor efficacy against
tumor models with even greater taxane resistance might be
informative in distinguishing direct effects on either tumor or
stromal compartments.
In view of the recent clinical trial results demonstrating the
survival benefit of intraperitoneal versus intravenous admin-
istration of chemotherapeutic agents for ovarian cancer pa-
tients with small-volume peritoneal disease, we confined our
preclinical evaluation of HA-TXL to the intraperitoneal ad-
ministration route. However, this does not exclude the pos-
sibility that the intravenous administration route would also
demonstrate antitumor efficacy, although such direct expo-
sure to CD44(+) leukocyte populations might have undesired
effects on immune function, nor does it address the actual
pharmacological behavior and mode of uptake of HA-TXL
administered intraperitoneally. Although a reasonable model
for the latter would certainly be one involving a direct uptake
of HA-TXL from the peritoneum into the tumor milieu, one
cannot currently exclude the possibility of clearance from the
peritoneum, followed by systemic distribution and extra-
vasation from the tumor vasculature in small tumor foci
present at the time of treatment [45]. Furthermore, another
setting in which HA-TXL–based therapy might have a
sound rationale is in metronomic therapy, as the absence
of polyoxyl 40 hydrogenated castor oil (Cremophor; Sigma-
Aldrich, St. Louis, MO) would obviate the interference of
this excipient with the antiangiogenic effects of taxanes—
paclitaxel in particular.
A number of variables to be optimized in future preclinical
studies include the size of the HA backbone, as this should
affect the rates of HA-TXL clearance from the peritoneum
and from the vascular compartment, as well as the opportu-
nity for multiple CD44/HA binding interactions, and hence the
resultant avidity. Similarly, the extent of paclitaxel substitu-
tion in the current study was intentionally kept at f 10% or
less of the available carboxyl groups on the HA, with the
expectation that this would have a minimal effect on HA/
CD44 interactions. However, higher loading may be accept-
able, particularly with longer HA chains that allow multiple
receptor interactions.
Based on these promising results in antitumor efficacy
studies, we conclude that HA-based prodrugs, HA-TXL in
particular, merit further preclinical development and evalua-
tion. Furthermore, with increasing evidence for the expres-
sion of CD44 on cancer stem cells of diverse origins [46–53],
the ability to selectively target chemotherapeutic agents to
CD44 may achieve marked significance.
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